| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| CASI Pharmaceuticals Inc. | CNCT19 (CD19 CAR-T) - (B-NHL) | Non-Hodgkin Lymphoma (NHL) / Acute lymphoblastic leukemia (ALL) | Phase 2 | Enrollment Initiation | Intravenous | Oncology |
| Cassava Sciences Inc. | Simufilam (PTI-125) - (REFOCUS-ALZ) | Mild-to-Moderate Alzheimer's Disease | Phase 3 | Trial Discontinued | Oral | Neurology |
| Cassava Sciences Inc. | Simufilam (PTI-125-04) | Alzheimer's Disease | Phase 3 | Trial Discontinued | Oral | Neurology |
| Cassava Sciences Inc. | Simufilam (PTI-125) - (RETHINK-ALZ) | Alzheimer’s disease | Phase 3 | Trial Discontinued | Oral | Neurology |
| Cassava Sciences Inc. | Simufilam - (CMS) | Alzheimer's disease | Phase 3 | Ongoing | Oral | Neurology |
| Catalyst Pharmaceuticals Inc. | FIRDAPSE (amifampridine) | Spinal Muscular Atrophy (SMA) Type 3 | Phase 2 | Trial Discontinued | oral | Genetic Disorder |
| CDT Equity Inc. | AZD1656 | Renal Transplant | Phase 2 | Trial Planned | oral | Immunosuppressant |
| CDT Equity Inc. | AZD1656 | Systemic lupus erythematosus (including lupus nephritis) | Phase 2a | Trial Planned | oral | Immunology |